Esperion Therapeutics ESPR Unchanged at 313 RangeBound Trading 20260520 Google Assistant Privacy Concerns Raise Questions Around AI Governance and Regulatory Risk Veralto VLTO Q1 2026 Earnings Beat Revenue NA EPS 107 EU Negotiators Reach Agreement on Key Clauses of US Trade Deal Implementation Timeline Still Under Debate Banks Step Up Apprentice Hiring to Curb Costs and Broaden Customer Reach First FCNCO Delivers Q1 2026 Beat EPS 4486 vs 4059 Expected